Pfizer Corporation

Wyeth

Cindy Xudong Yang

Lakshmi Khandke

Annaliesa Sybil Anderson

Avvari Krishna Prasad

Amardeep Singh Bhupender Bhalla

Miguel Angel Garcia

Lei Hu

Leena Shriram Bagle

Kathrin Ute Jansen

Mark Edward Ruppen

Jianxin Gu

Jin-Hwan Kim

Rajesh Kumar Kainthan

Robert G K Donald

Paul A Liberator

Ingrid Lea Scully

Suddham Singh

Ronald Malone

Hanyoung Han

Zhaowei Jin

Ying Chen

Robert C Seid, Jr

The invention relates to immunogenic compositions comprising a capsular polysaccharide (CP) from, commonly referred to as group B streptococcus (GBS), conjugated to a carrier protein, and optionally including an aluminum-based adjuvant. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.

Immunogenic compositions and uses thereof

The invention relates to immunogenic compositions comprising a capsular polysaccharide (CP) from, commonly referred to as group B(GBS), conjugated to a carrier protein, and optionally including an aluminum-based adjuvant. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.

The invention relates to immunogenic polysaccharide-protein conjugates comprising a capsular polysaccharide (CP) from, commonly referred to as group B(GBS), and a carrier protein, wherein the CP is selected from the group consisting of serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII, and IX, and wherein the CP has a sialic acid level of greater than about 60%. The invention also relates to methods of making the conjugates and immunogenic compositions comprising the conjugates. The invention also relates to immunogenic compositions comprising polysaccharide-protein conjugates, wherein the conjugates comprise a CP from GBS serotype IV and at least one additional serotype. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.

Group Bpolysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof

[object Object]

The present invention addresses an ongoing need in the art to improve the stability of immunogenic compositions such as polysaccharide-protein conjugates and protein immunogens. The invention broadly relates to novel formulations which stabilize and inhibit precipitation of immunogenic compositions. More particularly, the invention described hereinafter, addresses a need in the art for formulations which stabilize and inhibit particulate formation (e.g., aggregation, precipitation) of immunogenic compositions which are processed, developed, formulated, manufactured and/or stored in container means such as fermentors, bioreactors, vials, flasks, bags, syringes, rubber stoppers, tubing and the like.

Formulations which stabilize and inhibit precipitation of immunogenic compositions

Growing community of inventors

Tappan, NY, United States of America

Cindy Xudong Yang